Association of CYP1B1 gene polymorphisms with susceptibility to endometrial cancer: A meta-analysis

European Journal of Cancer Prevention

Volumn 20, Issue 2, 2011, Pages 112-120

  Wang, Fang ^a   Zou, Yan Feng ^a   Sun, Guo Ping ^a   Su, Hong ^a   Huang, Fen ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

CYP1B1; endometrial cancer; genetic polymorphisms; meta analysis

Indexed keywords

CYTOCHROME P450 1B1;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DATA BASE; DNA POLYMORPHISM; ENDOMETRIUM CANCER; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79551535559     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e3283410193     Document Type: Article

References (36)

1. Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, et al. (2010). Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk. Cancer Epidemiol 34:328-37.
2. Bailey LR, Roodi N, Dupont WD, Parl FF (1998). Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 58:5038-5041.
3. Bandiera S, Weidlich S, Harth V, Broede P, Ko Y, Friedberg T (2005). Proteasomal degradation of human CYP1B1: effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression. Mol Pharmacol 67:435-443.
4. Bejjani BA, Lewis RA, Tomey KF, Anderson KL, Dueker DK, Jabak M, et al. (1998). Mutations in CYP1B1, the gene for cytochrome P4501B1, are the predominant cause of primary congenital glaucoma in Saudi Arabia. Am J Hum Genet 62:325-333.
5. Chen B, Qiu LX, Li Y, Xu W, Wang XL, Zhao WH, et al. (2010). The CYP1B1 Leu432Val polymorphism contributes to lung cancer risk: evidence from 6501 subjects. Lung Cancer 70:247-252. doi:10.1016/j.lungcan.2010.03.011.
6. Cochran WG (1954). The combination of estimates from different experiments. Biometrics 10:101-129.
7. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
8. Doherty JA, Weiss NS, Freeman RJ, Dightman DA, Thornton PJ, Houck JR, et al. (2005). Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 14:357-366.
9. Economopoulos KP, Sergentanis TN (2010). Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 124:883-887.
10. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. Br Med J 315:629-634.
11. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF (2000). Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 60: 3440-3444.
12. Henderson BE, Feigelson HS (2000). Hormonal carcinogenesis. Carcinogenesis 21:427-433.
13. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-1558.
14. Hirata H, Hinoda Y, Okayama N, Suehiro Y, Kawamoto K, Kikuno N, et al. (2008). CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer 112:1964-1973.
15. Jordan VC (2000). Antiestrogens: clinical applications of pharmacology. J Soc Gynecol Investig 7:S47-S48.
16. Kaminsky LS, Spivack SD (1999). Cytochromes P450 and cancer. Mol Aspects Med 20:70-84, 137.
17. Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW (2000). Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 1:379-388.
18. Landi MT, Bergen AW, Baccarelli A, Patterson DG Jr, Grassman J, Ter-Minassian M, et al. (2005). CYP1A1 and CYP1B1 genotypes, haplotypes, and TCDDinduced gene expression in subjects from Seveso, Italy. Toxicology 207: 191-202.
19. Mantel N, Hansel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748.
20. McGrath M, Hankinson SE, Arbeitman L, Colditz GA, Hunter DJ, De Vivo I (2004). Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility. Carcinogenesis 25:559-565.
21. Meyer UA, Gut J, Kronbach T, Skoda C, Meier UT, Catin T, et al. (1986). The molecular mechanisms of two common polymorphisms of drug oxidation evidence for functional changes in cytochrome P-450 isozymes catalyzing bufuralol and mephenytoin oxidation. Xenobiotica 16:449-464.
22. Niwa K, Imai A, Hashimoto M, Yokoyama Y, Mori H, Matsuda Y, et al. (2000). A case-control study of uterine endometrial cancer of pre- and postmenopausal women. Oncol Rep 7:89-93.
23. Rebbeck TR, Troxel AB, Wang Y, Walker AH, Panossian S, Gallagher S, et al. (2006). Estrogen sulfation genes, hormone replacement therapy and endometrial cancer risk. J Natl Cancer Inst 98:1311-1320.
24. Roos PH, Bolt HM (2005). Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1. Expert Opin Drug Metab Toxicol 1:187-202.
25. Rylander-Rudqvist T, Wedrén S, Jonasdottir G, Ahlberg S, Weiderpass E, Persson I, et al. (2004). Cytochrome P450 1B1 gene polymorphisms and postmenopausal endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 13:1515-1520.
26. Saintot M, Malaveille C, Hautefeuille A, Gerber M (2004). Interaction between genetic polymorphism of cytochrome P450-1B1 and environmental pollutants in breast cancer risk. Eur J Cancer Prev. 13:83-86.
27. Sasaki M, Kaneuchi M, Fujimoto S, Tanaka Y, Dahiya R (2003a). CYP1B1 gene in endometrial cancer. Mol Cell Endocrinol 202:171-176.
28. Sasaki M, Tanaka Y, Kaneuchi M, Sakuragi N, Dahiya R (2003b). CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor alpha and estrogen receptor beta expressions. Cancer Res 63:3913-3918.
29. Shah PP, Singh AP, Singh M, Mathur N, Mishra BN, Pant MC, et al. (2008). Association of functionally important polymorphisms in cytochrome P4501B1 with lung cancer. Mutat Res 643:4-10.
30. Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM, et al. (1999). Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 20:1607-1613.
31. Sliwinski T, Sitarek P, Stetkiewicz T, Sobczuk A, Blasiak J (2010). Polymorphism of the ERalpha and CYP1B1 genes in endometrial cancer in a Polish subpopulation. J Obstet Gynaecol Res 36:311-317.
32. Stoilov I, Akarsu AN, Alozie I, Child A, Barsoum-Homsy M, Turacli ME, et al. (1998). Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet 62:573-584.
33. Tao MH, Cai Q, Xu WH, Kataoka N,WenW, Zheng W, et al. (2006). Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and endometrial cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 15:2570-2573.
34. Zhang D, Lu AN, Liao YM (2007). Association between gene polymorphism of CYP1B1 and susceptibility to endometrial cancer. Cent Plains Med J 34:9-10.
35. Zhu ZY, Mu YQ, Fu XM, Wang XY, Zhao FX (2008). Association between gene polymorphism of CYP1B1 and susceptibility to endometrial cancer. Mod Med Journal of China 10:1-5.
36. Zimarina TC, Kristensen VN, Imianitov EN, Bershten LM (2004). Polymorphisms of CYP1B1 and COMT in breast and endometrial cancer. Mol Biol (Mosk) 38:386-393.